Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells
Adoptive cell therapy (ACT) using autologous cytokine-induced killer (CIK) cells is a promising treatment for metastatic carcinomas. In this study, we investigated the impact of RetroNectin on the proliferation, phenotype alternation, cytokine secretion, and cytotoxic activity of CIK cells from panc...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2016/5706814 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558156816842752 |
|---|---|
| author | Lu Han Yi-Man Shang Yong-Ping Song Quan-Li Gao |
| author_facet | Lu Han Yi-Man Shang Yong-Ping Song Quan-Li Gao |
| author_sort | Lu Han |
| collection | DOAJ |
| description | Adoptive cell therapy (ACT) using autologous cytokine-induced killer (CIK) cells is a promising treatment for metastatic carcinomas. In this study, we investigated the impact of RetroNectin on the proliferation, phenotype alternation, cytokine secretion, and cytotoxic activity of CIK cells from pancreatic cancer patients. Furthermore, we treated 13 patients with metastatic or locally advanced pancreatic cancer using autologous RetroNectin-activated CIK cells (R-CIK cells) alone or in combination with chemotherapy. Compared with only CD3 activated CIK cells (OKT-CIK cells), R-CIK cells showed stronger and faster proliferative ability, with a lower ratio of spontaneous apoptosis. Moreover, this ability continued after IL-2 was withdrawn from the culture system. R-CIK cells could also secrete higher levels of IL-2 and lower levels of IL-4 and IL-5 versus OKT-CIK cells. There was no difference between OKT-CIK and R-CIK cells in cytotoxic ability against lymphoma cell line K562. In patients who received auto-R-CIK cell infusion therapy, the overall objective response rate was 23.1%. Median survival time (mOS) after first R-CIK cell infusion was 10.57 months; the 1-year survival rate was 38.5%. No serious toxicity was associated with R-CIK cell infusion. In conclusion, RetroNectin may enhance antitumor activity of CIK cells: it is safe for use in treating pancreatic cancer. |
| format | Article |
| id | doaj-art-1e8b9df8813c42689549da8f7051939c |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-1e8b9df8813c42689549da8f7051939c2025-02-03T01:32:57ZengWileyJournal of Immunology Research2314-88612314-71562016-01-01201610.1155/2016/57068145706814Biological Character of RetroNectin Activated Cytokine-Induced Killer CellsLu Han0Yi-Man Shang1Yong-Ping Song2Quan-Li Gao3Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan 450008, ChinaDepartment of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan 450008, ChinaDepartment of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan 450008, ChinaDepartment of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan 450008, ChinaAdoptive cell therapy (ACT) using autologous cytokine-induced killer (CIK) cells is a promising treatment for metastatic carcinomas. In this study, we investigated the impact of RetroNectin on the proliferation, phenotype alternation, cytokine secretion, and cytotoxic activity of CIK cells from pancreatic cancer patients. Furthermore, we treated 13 patients with metastatic or locally advanced pancreatic cancer using autologous RetroNectin-activated CIK cells (R-CIK cells) alone or in combination with chemotherapy. Compared with only CD3 activated CIK cells (OKT-CIK cells), R-CIK cells showed stronger and faster proliferative ability, with a lower ratio of spontaneous apoptosis. Moreover, this ability continued after IL-2 was withdrawn from the culture system. R-CIK cells could also secrete higher levels of IL-2 and lower levels of IL-4 and IL-5 versus OKT-CIK cells. There was no difference between OKT-CIK and R-CIK cells in cytotoxic ability against lymphoma cell line K562. In patients who received auto-R-CIK cell infusion therapy, the overall objective response rate was 23.1%. Median survival time (mOS) after first R-CIK cell infusion was 10.57 months; the 1-year survival rate was 38.5%. No serious toxicity was associated with R-CIK cell infusion. In conclusion, RetroNectin may enhance antitumor activity of CIK cells: it is safe for use in treating pancreatic cancer.http://dx.doi.org/10.1155/2016/5706814 |
| spellingShingle | Lu Han Yi-Man Shang Yong-Ping Song Quan-Li Gao Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells Journal of Immunology Research |
| title | Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells |
| title_full | Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells |
| title_fullStr | Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells |
| title_full_unstemmed | Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells |
| title_short | Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells |
| title_sort | biological character of retronectin activated cytokine induced killer cells |
| url | http://dx.doi.org/10.1155/2016/5706814 |
| work_keys_str_mv | AT luhan biologicalcharacterofretronectinactivatedcytokineinducedkillercells AT yimanshang biologicalcharacterofretronectinactivatedcytokineinducedkillercells AT yongpingsong biologicalcharacterofretronectinactivatedcytokineinducedkillercells AT quanligao biologicalcharacterofretronectinactivatedcytokineinducedkillercells |